Saturday, July 11, 2026

pharma · Diarrhea-predominant Irritable Bowel Syndrome

Chengdu University of

Chengdu University of is a pharma organization headquartered in CN. Primary therapeutic focus areas include Diarrhea-predominant Irritable Bowel Syndrome. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), an

CN HQ
256 Employees
NMPA registrant Type
Company details
Status
Public
HQ
CN
Employees
256
Programs
1
Drugs
1
Patents
0
Clinical program

Loperamide

Phase 3 · small molecule · Diarrhea-predominant Irritable Bowel Syndrome

Loperamide for Diarrhea-predominant Irritable Bowel Syndrome is a Phase 3 program (small_molecule) at Chengdu University of Traditional Chinese Medicine with 1 ClinicalTrials.gov record(s).

Internal code 2011CB5200-Fd

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Chengdu University of Traditional Chinese Medicine
Phase
Phase 3
Modality
small_molecule
Indication
Diarrhea-predominant Irritable Bowel Syndrome
Status
completed
Trials
1